Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Velzatinib · 2 trials · 2 indications
PFS is defined as time from the date of randomization to the date of disease progression or death due to any cause, whichever occurs first.
ORR is defined as the percent of participants reaching confirmed complete response (CR) or partial response (PR).
| Arm | Type | Description |
|---|---|---|
| Velzatinib | EXPERIMENTAL | - |
| Imatinib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Velzatinib | DRUG | Velzatinib will be administered |
| Imatinib | DRUG | Imatinib will be administered |
Inclusion Criteria: * Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed consent form (ICF). * Has histologically or cytologically confirmed GIST that is metastatic and/or surgically unresectable. * Has ...
Velzatinib is an investigational small molecule kinase inhibitor being studied for the treatment of gastrointestinal neoplasms, including gastrointestinal stromal tumors (GIST). It is being evaluated in patients with previously untreated metastatic and/or unresectable GIST, as well as in those whose disease has progressed after prior therapies.
Velzatinib is being developed by GSK plc, a global biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol GSK.
Velzatinib is a kinase inhibitor, as indicated by its '-tinib' suffix. It is designed to target specific kinases involved in tumor growth, though the exact molecular target has not been specified in available information.
Velzatinib is currently in Phase 2 clinical development. It is being investigated in a Phase 2 study for patients with metastatic and/or unresectable gastrointestinal stromal tumors after prior treatment with imatinib, sunitinib, regorafenib, and pimitespib.
Velzatinib is being studied in two clinical trials. NCT07585266 is a Phase 3 study comparing Velzatinib with imatinib in previously untreated metastatic and/or unresectable GIST, currently recruiting 800 participants. NCT07689201 is a Phase 2 study in patients with GIST after prior therapies, not yet recruiting.
No, Velzatinib is not the same as imatinib. Velzatinib is an investigational drug being compared with imatinib in a clinical trial for previously untreated gastrointestinal stromal tumors. Imatinib is an established standard treatment for this condition.